Drugs for Neglected Diseases Initiative

Drugs for Neglected Diseases Initiative
Name	Drugs for Neglected Diseases Initiative
Founded	2003
Founders	Médecins Sans Frontières, WHO Special Programme for Research and Training in Tropical Diseases
Type	Non-profit organization
Purpose	Research and development of treatments for neglected tropical diseases
Headquarters	Geneva, Switzerland
Region served	Global South

Drugs for Neglected Diseases Initiative

Drugs for Neglected Diseases Initiative is a non-profit research and development organization established to develop affordable treatments for neglected tropical diseases affecting populations in the Global South. It was founded through collaboration among Médecins Sans Frontières, global health actors such as the World Health Organization, and public health institutions to translate clinical need into new therapies. The initiative operates at the intersection of translational research, policy advocacy, and global health partnerships, engaging with pharmaceutical companies, academic centers, and multilateral funders.

History

The organization emerged in the early 2000s after advocacy by Médecins Sans Frontières drew attention at events including the World Health Assembly and consultations with World Bank and United Nations agencies. Its creation was informed by precedents such as the WHO Special Programme for Research and Training in Tropical Diseases and initiatives like the Global Alliance for Vaccines and Immunization that sought innovative financing for neglected conditions. Early work involved forging agreements with pharmaceutical firms represented at forums such as the International Federation of Pharmaceutical Manufacturers & Associations and academic partnerships with institutions like the London School of Hygiene & Tropical Medicine and Institut Pasteur. Over subsequent decades the organization expanded programs addressing diseases endemic in regions served by African Union, Association of Southeast Asian Nations, and Pan American Health Organization members.

Mission and Objectives

The initiative’s mission aligns with agendas set by the United Nations Millennium Development Goals and later the United Nations Sustainable Development Goals to reduce disease burden in low-income settings. Objectives include discovery of new chemical entities, optimization of existing medicines, implementation of clinical trials in endemic countries such as Uganda, India, and Brazil, and ensuring access through regulatory pathways involving authorities like the European Medicines Agency and national drug regulators. It emphasizes capacity building with partners such as University of Oxford, University of São Paulo, and Makerere University to strengthen research networks across continents.

Research and Development Programs

R&D programs span diseases historically neglected by commercial markets, including projects on sleeping sickness (human African trypanosomiasis), visceral leishmaniasis, Chagas disease, and a range of helminthiases. Preclinical chemistry and target identification work has been undertaken with collaborators like Novartis, Sanofi, and academic groups at University of Dundee and Rockefeller University. Clinical development has been coordinated in trial sites linked to Institute of Tropical Medicine (Antwerp), Kilifi County Hospital, and Oswaldo Cruz Foundation. Product portfolios have included new fixed-dose combinations, reformulations for pediatric use, and novel oral compounds tested in trials governed by standards from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and overseen by ethics review boards modeled after those at Harvard Medical School and Johns Hopkins University.

Partnerships and Funding

Funding sources and partnerships have combined philanthropic donors such as the Bill & Melinda Gates Foundation and the Wellcome Trust with public funders like the United Kingdom Department for International Development and the European Commission. Collaborative agreements with pharmaceutical corporations including GSK, Roche, and smaller biotech firms have enabled access to compound libraries and manufacturing capacity. The initiative has engaged multilateral partners such as World Health Organization programs and regional bodies like the African Development Bank to facilitate uptake and policy alignment. Contract research organizations and procurement mechanisms linked to Global Fund to Fight AIDS, Tuberculosis and Malaria and UNICEF have been used for distribution and scale-up.

Impact and Notable Achievements

Notable achievements include advancement of new treatments through regulatory approvals and prequalification processes managed by the World Health Organization, enabling improved regimens for diseases prevalent in Sudan, Bangladesh, and Nepal. The initiative has supported paediatric formulations that addressed gaps identified in studies by Centers for Disease Control and Prevention and expanded access initiatives consistent with recommendations from panels convened by The Lancet. It contributed to capacity building at sites that later participated in vaccine trials connected to collaborations with NIH and European & Developing Countries Clinical Trials Partnership. Partnerships helped reduce treatment delivery barriers in campaigns run alongside UNICEF and national ministries of health.

Governance and Organizational Structure

Governance has incorporated a board with representatives from academia, philanthropy, and global health organizations similar to governance models used by the Global Fund and Gavi, the Vaccine Alliance. Executive leadership has coordinated scientific advisory committees drawing expertise from institutions like Imperial College London, Karolinska Institute, and University of Cape Town. Operational units include drug development, clinical operations, access and policy, and country engagement teams liaising with national ministries such as those of Kenya, Ethiopia, and Mozambique.

Criticisms and Challenges

Critiques have addressed sustainable financing reminiscent of debates around GAVI and concerns raised in analyses by think tanks linked to Brookings Institution and Chatham House about scalability and dependence on donor cycles. Operational challenges include conducting trials in resource-limited settings alongside regulatory complexity involving authorities like the Food and Drug Administration and ensuring technology transfer with industrial partners such as Cipla and Dr. Reddy's Laboratories. Balancing intellectual property considerations with open-access advocacy from groups aligned with Open Society Foundations has been a recurring policy discussion.

Category:Non-profit medical research organizations